Cancer Genomics ONLINE - Webinar 3: Cancer epigenetics and detecting methylation signatures

Cancer is one of the diseases that has been most affected by the advances in sequencing capabilities. By interrogating the cancer genome, we have already been able to advance our ability to diagnose, characterise and develop new drugs for cancers.

However, cancer is complex. Its genome evolves rapidly and as with all biological systems, changes to the genome cause a cascade of biological changes that accelerates oncogenesis.

How can we harness the power of the latest omics technologies to better understand and treat cancer in 2022 and beyond?

Join us for Cancer Genomics ONLINE, as we delve into the latest research which are providing clues to the complexities of the genome and its environment, how we can scale our ability to translate these findings to patient benefit, and how going “beyond the genome” may be the next step in improving cancer care.

Webinar 3: Cancer epigenetics and detecting methylation signatures

19th July, 3pm BST/ 4pm CET/ 10am EST

With DNA methylation being long regarded as a hallmark of cancer, recent advances in detection technology have shown great promise in the utility of using methylation status as a tool to diagnose cancer early. However, translating these into the clinic remains slow.

In this webinar, we highlight advances in “going beyond the genome” for cancer diagnostics and address the challenges of widespread clinical utility.

The Promise of Multicancer Early Detection – Eric Klein, Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Case Western Reserve University

DNA methylation age as a biomarker for cancer - Chungho Lau, Research Associate, Imperial College London

Leading the way in target enrichment: Exceptional performance, improved efficiency and rapid customization of targeted methylation sequencing - Bryan N. Höglund, Senior Manager - NGS Business Development, Twist Bioscience

mDETECT, a suite of second generation liquid biopsies for multiple cancers – Christopher Mueller, Professor, Queen's Cancer Research Institute, Queen’s University

Previous webinars in the series:

Webinar 1: Interrogating and targeting the complexities of the cancer genome

Now available on demand - Register here

Since the discovery of the “cancer genome,” we have increasingly become aware of its complexities and its interactions with the microenvironment, the immune system, drivers of metastasis and beyond.

In this webinar, we will highlight how advanced omics technologies are unravelling the complexities of the cancer genome and beyond; and highlight how these are providing insights that could translate to actionable insights.

Using machine learning to predict driver variants in the human cancer genome – Colin Campbell, Reader in Mathematics for Information Technology, University of Bristol

Spatial CRISPR genomics identifies regulators of the tumor microenvironment – Brian Brown, Director, Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, Mount Sinai Medical Center

Targeting oncogenic long noncoding RNAs for cancer therapy – Tao Liu, Associate Professor & Group Leader – Gene Dysregulation Group, Children's Cancer Institute Australia, The University of New South Wales

Webinar 2: Clinical cancer genomics in 2022 and beyond

Now available on demand - Register here

Despite the advances in next-generation sequencing, opportunities remain to better utilise genomic capabilities for cancer detection, characterisation, and monitoring.

This webinar will cover the latest in robust sequencing of cancers in the clinics, and how we can scale up our capabilities to better support patients going forward.

Improving accuracy and consistency of variant interpretation for cancer susceptibility genes – Alice Garrett, Clinical Research Fellow, Institute of Cancer Research

Lab Automation for Cancer Genomics: Work Smarter – Craig Johnston, Diagnostics & Genomics Lead, Automata

Integrating whole genome sequencing into clinical practice for cancer patients – Alona Sosinsky, Scientific Director of Cancer, Genomics England